Is There Already a Need of Reckoning on Cancer Immunotherapy?
المؤلفون الرئيسيون: | Pierpaolo Correale, Francesca Pentimalli, Giovanni Baglio, Marjia Krstic-Demonacos, Rita Emilena Saladino, Antonio Giordano, Luciano Mutti |
---|---|
التنسيق: | مقال |
اللغة: | English |
منشور في: |
Frontiers Media S.A.
2021-03-01
|
سلاسل: | Frontiers in Pharmacology |
الموضوعات: | |
الوصول للمادة أونلاين: | https://www.frontiersin.org/articles/10.3389/fphar.2021.638279/full |
مواد مشابهة
-
Coronavirus Disease (Covid-19): What Are We Learning in a Country With High Mortality Rate?
حسب: Luciano Mutti, وآخرون
منشور في: (2020-05-01) -
Immune Checkpoint Inhibitor Uptake in Real-World Patients With Malignant Pleural Mesothelioma
حسب: Roger Y. Kim, MD, وآخرون
منشور في: (2021-06-01) -
Intratumor microbiota as a novel potential prognostic indicator in mesothelioma
حسب: Francesca Pentimalli, وآخرون
منشور في: (2023-03-01) -
Current status and progress in immunotherapy for malignant pleural mesothelioma
حسب: Boyang Sun, وآخرون
منشور في: (2022-06-01) -
Distinctive Role of the Systemic Inflammatory Profile in Non-Small-Cell Lung Cancer Younger and Elderly Patients Treated with a PD-1 Immune Checkpoint Blockade: A Real-World Retrospective Multi-Institutional Analysis
حسب: Valerio Nardone, وآخرون
منشور في: (2021-11-01)